CD162 (PSGL-1) Monoclonal Antibody (FLEG), APC, eBioscience™, Invitrogen™

Description

• Description: This FLEG monoclonal antibody recognizes human CD162, which is also known as P-selectin glyocoprotein ligand-1 (PSGL-1)
• This 120-kDa protein exists as a homodimer on the surface of monocytes, neutrophils, granulocytes, peripheral T cells, some B cells, and a subset of CD34+ hematopoietic progenitor cells (HPCs) in the bone marrow
• CD162 binds CD62P (P-selectin), CD62E (E-selectin), and CD62L (L-selectin) to mediate leukocyte interactions with each other as well as with activated platelets and endothelium
• Thus, CD162 plays a critical role in leukocyte adhesion and rolling
• Furthermore, the binding of CD162 to P-selectin on HPCs has been demonstrated to inhibit hematopoiesis
• Studies have also demonstrated CD162 as the receptor for enterovirus 71
• Applications Reported: This FLEG antibody has been reported for use in flow cytometric analysis
• Applications Tested: This FLEG antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.125 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD162 (PSGL-1) is a 120 kDa homodimer protein found on the surface of leukocytes and platelets
• CD162 is known to bind CD62P (P-selectin), CD62L (L-selectin), and to a lower degree CD62E (E-selectin)
• These interactions play a critical role in leukocyte adhesion, rolling and extravasation
• CD162 has been shown to be an important immune marker of T cell exhaustion in chronic viral infections and cancer.